A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)

Non-Small Cell Lung Cancer Clinical Trial

Official title:

A Randomized, Controlled, Open-Label, Multicenter, Phase II Study of the Safety and Efficacy of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00434226
• Other study ID #: AVF3996g
• Status: Terminated
• Phase: Phase 2
• First received: February 11, 2007
• Last updated: July 9, 2009
• Start date: March 2007

Study information

• Verified date: July 2009
• Source: Genentech, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a Phase II, randomized, controlled, open-label, multicenter trial designed to provide a preliminary assessment of the safety and efficacy of sunitinib when combined with carboplatin and paclitaxel chemotherapy and bevacizumab in patients with locally advanced, recurrent or metastatic NSCLC who have not received prior systemic therapy for NSCLC. All patients will have advanced, histologically or cytologically confirmed NSCLC (Stage IIIb with pleural effusions, Stage IV, or recurrent).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 56
• Est. primary completion date: April 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed Informed Consent Form

• Age = 18 years

• Advanced histologically or cytologically confirmed NSCLC (Stage IIIb with malignant pleural or pericardial effusion, Stage IV, or recurrent)

• Measurable or non-measurable disease

• Patients with treated brain metastases are eligible if there is no evidence of progression or hemorrhage after treatment, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period (brain imaging to be competed Day -7 to Day 1).

• Prior treatment for CNS disease as deemed appropriate by the treating physician

• ECOG performance status 0 or 1

• Ability and willingness to comply with study and follow-up procedures

Exclusion Criteria:

• Prior systemic chemotherapy for metastatic disease

• Active malignancy other than lung cancer

• Current, recent, or planned participation in another experimental drug study

• Prior treatment with anti-VEGF agent or agents targeting similar pathways as sunitinib

• Adjuvant chemotherapy or prior combined modality neoadjuvant therapy (chemotherapy plus radiotherapy with or without surgery) within 6 months prior to Day 1 of Cycle 1

• Life expectancy of < 12 weeks

• Current, recent, or planned participation in an experimental drug study

• Inability to take oral medication or requirement of IV alimentation or total parenteral nutrition, or prior surgical procedures affecting absorption

• Inadequate organ function

• Known evidence of disseminated intravascular coagulopathy

• Active infection or fever > 38.5°C within 3 days prior to Day 1 of Cycle 1

• Untreated abnormal thyroid function tests as defined by institutional standards (patients with controlled hypothyroidism are eligible for study participation)

• Any other medical condition(s) (including mental illness or substance abuse) deemed by the clinician to be likely to interfere with a patient's ability to provide informed consent, cooperate, or participate in the study, or to interfere with the interpretation of the results

• Intrathoracic lung carcinoma of squamous cell histology

• Known CNS disease except for treated brain metastases

• Inadequately controlled hypertension

• Prior history of hypertensive crisis or hypertensive encephalopathy

• New York Heart Association (NYHA) Class II or greater CHF

• History of myocardial infarction or unstable angina within 12 months prior to Day 1 of Cycle 1

• History of stroke or transient ischemic attack within 12 months prior to Day 1 of Cycle 1

• Significant vascular disease (e.g., aortic aneurysm, aortic dissection) or recent peripheral arterial thrombosis within 6 months prior to Day 1 of Cycle 1

• History of hemoptysis within 1 month prior to Day 1 of Cycle 1

• Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)

• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 of Cycle 1 or anticipation of need for major surgical procedure during the course of the study

• Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1 of Cycle 1

• History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1 of Cycle 1

• Serious, non-healing wound, active ulcer, or untreated bone fracture

• Proteinuria at screening, as demonstrated by a urine protein/creatinine ratio of = 1.0 at screening

• Known hypersensitivity to any component of bevacizumab or sunitinib

• Pregnancy (positive pregnancy test) or lactation

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-Small Cell Lung Cancer

Intervention

Drug:
• bevacizumab
Intravenously at a dose of 15mg/kg on the first day of each 21-day cycle
• sunitinib
25 mg/day for 2 weeks, followed by 1 week of rest
• carboplatin
On the first day of each cycle for 4 cycles
• paclitaxel
On the first day of each cycle for 4 cycles

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Genentech, Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Best Response		From randomization until disease progression/recurrence	No
Secondary	Serious Adverse Events		60 days following the last administration of study treatment	No
Secondary	Incidence of Grade = 3 Adverse Events		60 days following the last administration of study treatment	No
Secondary	Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction		60 days following the last administration of study treatment	No
Secondary	Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption		60 days following the last administration of study treatment	No